At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 106 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain: A Randomized Controlled Trial
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·interventional·Posted Sep 30, 2016·Updated Apr 15, 2021
In Brief
A Phase 3 clinical trial evaluating Ketamine and Placebo for Chronic Pain. Completed, enrolled 106 participants across 1 site.
Detailed Summary
This is a prospective, randomized controlled trial which will be conducted to determine whether sub-dissociative dose ketamine (SDDK) can improve pain control in subjects with chronic pain syndrome presenting to the emergency department with exacerbation of their chronic pain. The investigators also aim to determine whether use of SDDK can reduce the amount of subsequent opioid pain medications required for adequate pain relief in this population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain
CountriesUnited States
CollaboratorsUnited States Air Force Research Laboratory
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartMay 2017
Primary CompletionJun 2018
Study CompletionSep 2019
TodayJul 2026
First PostedSep 30, 2016
Enrollment StartMay 1, 2017
Primary CompletionJun 22, 2018
Study CompletionSep 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.8 years ago
Interventions
Ketaminedrug
sub-dissociative ketamine
Placebodrug
Normal Saline